Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19.

Chandan, Joht Singh, Zemedikun, Dawit Tefra, Thayakaran, Rasiah, Byne, Nathan, Dhalla, Samir, Acosta-Mena, Dionisio, Gokhale, Krishna M, Thomas, Tom, Sainsbury, Christopher, Subramanian, Anuradhaa, Cooper, Jennifer, Anand, Astha, Okoth, Kelvin O, Wang, Jingya, Adderley, Nicola J, Taverner, Thomas, Denniston, Alastair K, Lord, Janet, Thomas, G Neil, Buckley, Christopher D, Raza, Karim, Bhala, Neeraj, Nirantharakumar, Krishnarajah and Haroon, Shamil (2021) Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19. Arthritis & rheumatology (Hoboken, N.J.), 73 (5). pp. 731-739. ISSN 2326-5205. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

[img] Text (PDF file format)
art.41593 - Published Version
Available under License Creative Commons Attribution 4.0.

Download (19kB)
Official URL: http://onlinelibrary.wiley.com/journal/10.1002/(IS...

Abstract

OBJECTIVE

To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID-19) compared to the use of other common analgesics.

METHODS

We performed a propensity score-matched cohort study with active comparators, using a large UK primary care data set. The cohort consisted of adult patients age ≥18 years with osteoarthritis (OA) who were followed up from January 30 to July 31, 2020. Patients prescribed an NSAID (excluding topical preparations) were compared to those prescribed either co-codamol (paracetamol and codeine) or co-dydramol (paracetamol and dihydrocodeine). A total of 13,202 patients prescribed NSAIDs were identified, compared to 12,457 patients prescribed the comparator drugs. The primary outcome measure was the documentation of suspected or confirmed COVID-19, and the secondary outcome measure was all-cause mortality.

RESULTS

During follow-up, the incidence rates of suspected/confirmed COVID-19 were 15.4 and 19.9 per 1,000 person-years in the NSAID-exposed group and comparator group, respectively. Adjusted hazard ratios for suspected or confirmed COVID-19 among the unmatched and propensity score-matched OA cohorts, using data from clinical consultations in primary care settings, were 0.82 (95% confidence interval [95% CI] 0.62-1.10) and 0.79 (95% CI 0.57-1.11), respectively, and adjusted hazard ratios for the risk of all-cause mortality were 0.97 (95% CI 0.75-1.27) and 0.85 (95% CI 0.61-1.20), respectively. There was no effect modification by age or sex.

CONCLUSION

No increase in the risk of suspected or confirmed COVID-19 or mortality was observed among patients with OA in a primary care setting who were prescribed NSAIDs as compared to those who received comparator drugs. These results are reassuring and suggest that in the absence of acute illness, NSAIDs can be safely prescribed during the ongoing pandemic.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: W Public health. Health statistics. Occupational health. Health education
WD Diseases and disorders of systemic, metabolic or environmental origin
WD Diseases and disorders of systemic, metabolic or environmental origin > WD700 Systemic diseases, connective tissue disorders
WD Diseases and disorders of systemic, metabolic or environmental origin > WD811 Rheumatology
Divisions: Ambulatory Care > Rheumatology
Related URLs:
Depositing User: Jamie Edgar
Date Deposited: 17 May 2021 12:10
Last Modified: 17 May 2021 12:10
URI: http://www.repository.uhblibrary.co.uk/id/eprint/4321

Actions (login required)

View Item View Item